PF-06463922 is primarily utilized in the field of oncology as a targeted therapy for the treatment of various cancers. It functions as an ALK (anaplastic lymphoma kinase) inhibitor, making it particularly effective against non-small cell lung cancer (NSCLC) that is driven by ALK mutations. The compound is designed to penetrate the blood-brain barrier, which enhances its efficacy in treating brain metastases, a common complication in ALK-positive NSCLC patients. Its application extends to clinical trials where it is being evaluated for its potential to improve patient outcomes by reducing tumor growth and increasing progression-free survival. Additionally, PF-06463922 is being studied for its role in overcoming resistance to earlier generations of ALK inhibitors, offering a promising option for patients who have developed resistance to initial treatments.